Back to today’s briefing

Story perspectives

Atsena Therapeutics Secures $150M for Vision Gene Therapy

4/7/2025

33 5

Summary

Story summary

Atsena Therapeutics has raised an impressive $150 million in Series C funding to propel its groundbreaking gene therapy, ATSN-201, aimed at treating X-linked retinoschisis, a rare genetic disorder leading to blindness. With the Phase I/II LIGHTHOUSE trial underway, the company is poised to engage with the FDA on regulatory pathways, while also advancing additional preclinical initiatives.

1 of 1

Story summary

Atsena Therapeutics has raised an impressive $150 million in Series C funding to propel its groundbreaking gene therapy, ATSN-201, aimed at treating X-linked retinoschisis, a rare genetic disorder leading to blindness. With the Phase I/II LIGHTHOUSE trial underway, the company is poised to engage with the FDA on regulatory pathways, while also advancing additional preclinical initiatives.